Welcome to our dedicated page for Veracyte news (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte stock.
Veracyte, Inc. (Nasdaq: VCYT) is a global cancer diagnostics and genomic testing company whose news flow centers on clinical evidence, test performance, and financial results. The company describes its mission as transforming cancer care by empowering clinicians with high-value insights at key decision points in diagnosis and treatment. Its Veracyte Diagnostics Platform underpins tests such as Decipher Prostate, Afirma GSC, Prosigna, Decipher Bladder, and the Percepta Nasal Swab test, along with research tools like Afirma GRID and Decipher GRID.
On this page, readers can follow Veracyte news related to quarterly and annual financial results, including revenue and testing volume updates the company announces in earnings press releases and accompanying conference calls. Veracyte’s communications also highlight non-GAAP measures such as adjusted EBITDA and adjusted EBITDA margin, along with explanations of how these metrics are used internally and how they differ from GAAP figures.
Another major category of news involves clinical and scientific developments. Veracyte regularly reports on studies and abstracts that use its Afirma GRID and Decipher GRID platforms to develop and evaluate molecular signatures in thyroid and prostate cancer. Examples include publications on Afirma GRID-derived signatures to differentiate thyroid cancer risk groups and prospective validation data for biomarkers such as the PAM50 molecular signature in recurrent prostate cancer.
Investors and clinicians can also find announcements about Veracyte’s participation in healthcare and investor conferences, where management presents updates on the company’s diagnostics portfolio, research programs, and financial outlook. For ongoing insight into how Veracyte’s genomic tests and research tools are being used in practice and studied in trials, this news feed aggregates the company’s press releases and related updates in one place.
Veracyte (Nasdaq: VCYT) announced the inclusion of its Immunoscore Colon Cancer test in the new Pan-Asian ESMO Clinical Practice Guidelines for localized colon cancer diagnosis and treatment. The test, acquired through HalioDx in August 2021, assesses patient immune response and aids chemotherapy decisions for Stage II and III colon cancer patients. With increasing colorectal cancer cases in Asia, this recognition by Pan-Asian experts is a significant milestone, potentially facilitating wider reimbursement and patient access to the test.
Veracyte, Inc. (NASDAQ: VCYT) has published new data on its Afirma Genomic Sequencing Classifier (GSC) demonstrating its effectiveness in reducing unnecessary surgeries for patients with indeterminate thyroid nodules. The peer-reviewed study showed that Afirma GSC identified 30% more benign nodules compared to the original classifier, leading to a 41% reduction in surgeries compared to patients without molecular testing. The research reinforces the test's high sensitivity and specificity, indicating a shift in clinical practice for managing thyroid nodules.
Veracyte, Inc. (NASDAQ: VCYT) announced the presentation of three abstracts at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting from November 10-14, 2021. These abstracts focus on the company's Brightplex technology, acquired from HalioDx, which analyzes tumor micro-environments to enhance immunotherapy development. Corinne Danan, general manager of Biopharma, emphasized the importance of this technology in understanding therapeutic mechanisms. Veracyte aims to improve cancer treatment through innovative diagnostic solutions that speed up patient care.
Veracyte (NASDAQ: VCYT) presented new data at the ASTRO Annual Meeting 2021, indicating that its Decipher Prostate genomic classifier is effective in tailoring treatment for men with prostate cancer after radical prostatectomy. Results from a phase 3 trial involving 226 patients showed that those classified as high-risk using the Decipher tool had over double the likelihood of experiencing cancer progression with radiotherapy alone. This study highlights the potential for personalized treatment plans, enhancing outcomes for patients with rising PSA levels.
Veracyte (Nasdaq: VCYT) announced at the ASTRO 2021 Annual Meeting that its Decipher Prostate genomic classifier has validated the identification of patients with high-risk prostate cancer requiring intensified treatment. An analysis of biopsy samples indicated that high Decipher scores correlated with worse outcomes, including distant metastases and mortality. The data, derived from three phase 3 randomized trials, show that men with high-risk scores faced a cumulative incidence of metastases of 41% at 10 years. This validation may enhance personalized treatment decisions in clinical settings.
Veracyte (NASDAQ: VCYT) will present new data on its Decipher Prostate genomic test at the ASTRO Annual Meeting 2021, taking place from October 24-27 in Chicago. The studies focus on the test's effectiveness for newly diagnosed, clinically high-risk prostate cancer patients and those with biochemical disease progression after prostatectomy. Notable presentations include two oral sessions scheduled for October 25 and 26, showcasing its potential role in personalized treatment decision-making. This advancement in genomic science aims to enhance patient care and treatment outcomes.
Veracyte, Inc. (Nasdaq: VCYT) has published new data showing that its Decipher Bladder genomic classifier effectively identifies bladder tumors likely to respond to chemotherapy before radical cystectomy. The findings, detailed in a peer-reviewed study, may enhance treatment planning for muscle-invasive bladder cancer (MIBC) patients. In a study of 601 patients, non-luminal tumors significantly benefitted from neoadjuvant chemotherapy, improving overall survival by 10%. Veracyte aims to validate this test for routine clinical use.
Veracyte, Inc (NASDAQ: VCYT) will release its Q2 2021 financial results on November 9, after market close. Management will host a conference call at 4:30 p.m. ET to discuss the results and provide a business update. Investors can join via a toll-free number or through a live webcast. Veracyte specializes in diagnostics, leveraging genomic science to enhance cancer diagnosis and treatment decisions, helping patients avoid unnecessary procedures. The company continues to develop tests across various cancers.
Veracyte (NASDAQ: VCYT) announced new findings showing that its Envisia Genomic Classifier significantly enhances clinical decision-making in idiopathic pulmonary fibrosis (IPF). An oral presentation at the CHEST Annual Meeting on October 18 will highlight the results from a study involving over 100 pulmonologists. Key metrics include a 39% increase in IPF diagnosis and a boost in physician confidence, leading to a higher rate of treatment recommendations. This innovative test addresses the critical need for accurate diagnoses in a challenging medical area.
Veracyte (Nasdaq: VCYT) has announced expanded clinical validation data supporting the Percepta Nasal Swab test, which helps assess lung cancer risk in patients with lung nodules. This noninvasive test shows high sensitivity (97%) and negative predictive value (98%) for low-risk classifications, potentially reducing unnecessary invasive procedures. The test's performance is consistent across different nodule sizes and stages of non-small cell lung cancer (NSCLC). Veracyte is offering the test to selected clinical sites, aiming to build clinical utility data for reimbursement.